TY - JOUR
T1 - No evidence for cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic visitors
AU - Woestenberg, Petra J.
AU - King, Audrey J.
AU - van der Sande, Marianne A. B.
AU - Donken, Robine
AU - Leussink, Suzan
AU - van der Klis, Fiona R. M.
AU - Hoebe, Christian J. P. A.
AU - Bogaards, Johannes A.
AU - van Benthem, Birgit H. B.
AU - Med Microbiological Labs
AU - Public Hlth Serv
PY - 2017/4
Y1 - 2017/4
N2 - Objectives: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.Results: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results.Conclusions: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW. (C) 2017 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.
AB - Objectives: Data from a vaccine trial and from post-vaccine surveillance in the United Kingdom have suggested that the bivalent HPV-16/18 vaccine offers cross-protection against HPV-6/11 and protection against anogenital warts (AGW). We studied the effect of the bivalent vaccine on genital HPV-6/11 positivity and AGW in the Netherlands.Methods: We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional study among 16- to 24-year-old sexually transmitted infection (STI) clinic attendants. Vaginal self-swabs were analyzed for type specific HPV and AGW were diagnosed at the STI-clinic. Prevalence of HPV-6 and/or HPV-11 and AGW were compared between self-reported vaccinated and unvaccinated women by log-binomial regression analysis, adjusted for demographics and risk behavior.Results: Of the 1198 women included, 56% reported to be vaccinated at least once. Relative to unvaccinated women, the adjusted prevalence ratio (PR) for HPV-6/11 was 1.03 (95% confidence interval [CI] 0.74-1.43) for women vaccinated at least once. The crude PR for AGW was 0.67 (95% CI 0.22-2.07) for women vaccinated at least once. Adjustment did not change these results.Conclusions: We observed no cross-protective effect of the bivalent vaccine on genital HPV-6/11 positivity and a non-significant partially protective effect on AGW. (C) 2017 The Authors. Published by Elsevier Ltd on behalf of The British Infection Association.
KW - Human papillomavirus 6
KW - Human papillomavirus 11
KW - Condylomata acuminata
KW - Warts
KW - Vaccination
KW - Human papillomavirus vaccine, L1 type 16, 18
KW - Prevention & control
KW - RISK HPV TYPES
KW - GENITAL WARTS
KW - INTRAEPITHELIAL NEOPLASIA
KW - AS04-ADJUVANTED VACCINE
KW - ANOGENITAL WARTS
KW - CERVICAL-CANCER
KW - PAPILLOMAVIRUS
KW - NETHERLANDS
KW - EFFICACY
KW - WOMEN
U2 - 10.1016/j.jinf.2017.01.007
DO - 10.1016/j.jinf.2017.01.007
M3 - Article
C2 - 28126492
SN - 0163-4453
VL - 74
SP - 393
EP - 400
JO - Journal of Infection
JF - Journal of Infection
IS - 4
ER -